Project Grant R01AI189911
Award Date 8/12/25
Completion Date 7/31/30
Dollars Obligated $706K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rhode Island, USA
Similar Awards
- This Project Grant award of $1,553,810 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate a genomic surveillance approach for monitoring artemisinin resistance in Plasmodium falciparum malaria in Africa. The project aims to identify genetic mutations and altered biological functions associated with artemisinin resistance, which is a critical concern as resistance emerges...
- This federal Project Grant award of $791,864 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify molecular factors controlling chromatin organization and gene regulation in the malaria parasite Plasmodium falciparum. The research aims to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and sexual differentiation, with the goal...
- This $438,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support the development of new tools to facilitate drug discovery for proteasomes in parasitic diseases associated with poverty, including neglected tropical diseases (NTDs). The key objectives are to address two key bottlenecks in advancing parasite proteasome research: 1) the time-consuming and limited purification of native parasite 20S...
- The Project Grant award R01AI187153 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on identifying genetic factors associated with sexual stage development (gametocyte formation) in the malaria parasite Plasmodium falciparum. The $700,288 award, with a project period from Nov 2024 to Oct 2029, will fund a research project at the University of South Florida to perform...
- This $258,644 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to develop novel 4-aminoquinoline therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest malaria parasite. The grant recipient, Oregon Health & Science University, will use an iterative medicinal chemistry approach to select compounds with potent antiplasmodial activity, favorable pharmacokinetic...
- This $633,218 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research CFDA Program (93.855), supports research to characterize the mechanism of inhibition of the cholesterol transporter protein Pfncr1 in the malaria parasite. The research aims to use structural, physiological, genetic, and cell biological approaches to investigate two new inhibitors of Pfncr1 that are predicted to bind away from the...
- This $1,174,636 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) supports the development of next-generation ELQ compounds for the treatment and prevention of malaria. The research aims to identify novel, rapidly acting anti-malarial drugs to target the blood and liver stages of the Plasmodium falciparum parasite, as well as formulations suitable for long-acting...
- This $122,597 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to analyze the function and antibody-mediated inhibition of the malaria vaccine candidate protein PF3D7_1136200. The project aims to characterize this promising but previously uncharacterized blood-stage malaria antigen, with the goal of advancing development of a highly efficacious malaria vaccine. The...
- This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will fund research by The Trustees of Columbia University in the City of New York to identify and characterize the roles of non-coding RNAs in regulating drug-induced quiescence in Plasmodium falciparum, the parasite that causes malaria. The project aims to uncover novel epigenetic and epitranscriptomic mechanisms that enable...
- This $781,241 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), will support a systems analysis to understand the differential pharmacokinetics and protective efficacy of anti-malarial monoclonal antibodies (mAbs) in field trials. The research aims to leverage prospective clinical data, pharmacokinetic data, and biospecimens from a Phase 2 pediatric trial of the...